Lipidtarget® is a medical app developed
by Health Help Tools.
The APK has been available since June 2016.
Lipidtarget® has been downloaded 10+
times.
It's currently not in the top ranks on Google Play.
It's rated 0.00 out of 5 stars,
based on 0 ratings.
The last update of the app was on July 7, 2016.
Lipidtarget® has a content rating
"Everyone".
The latest APK available is 1.0.
Lipidtarget® costs $5.49 to download.
Description
Lipidtarget® is an application for health professionals with responsibility for prescription drugs, which aims to facilitate decision-making on the recommended lipid-lowering therapy in different clinical situations. Lipidtarget® recommendations are aligned with the strategy of "Treat to Target”, which consider Low Density Lipoprotein cholesterol (LDL-C) as the primary goal of treatment, and follows the leading European clinical practice guidelines 1.2, based on scientific evidence available 3. According to the lipid profile given, Lipidtarget® could make recommendations for the control of other objectives as non High Density Lipoprotein cholesterol (non HDL-C) and / or triglicéridos 4. Lipidtarget® makes recommendations but not requirements because they are a direct responsibility of the health professional who will account for this, the characteristics of the drug prescribed (on label) and clinical profile of the patient being treated. In this sense, Lipidtarget® should never replace the clinical judgment of health professionals. The authors of Lipidtarget® are not responsible of inappropriate, irresponsible or fraudulent use of any of the recommendations could give. BIBLIOGRAPHY
Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipideamias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1878. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines in cardiovascular disease prevention in clinical practice (version 2012). The Fith Joint Task Force of The European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in clinical Practice. Eur Heart J doi: 10.1093/eurheartj/ehs092 Mahley RW, Bersot TP. Goodman and Gilman's.The Pharmacological Basis of Therapeutics. New York: McGraw Hill; 2005. p. 933–66 Berglund, L.; Brunzell, J.D.; Goldberg, A.C.; Goldberg, I.J.; Sacks, F.; Murad, M.H.; Stalenhoef, A.F. Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97, 2969–2989.
Recent changes: A quick and easy tool. Developed by healthcare professionals for healthcare professionals .
Save time, in 3 quick steps Lipidtarget® recommends proper treatment to achieve the objectives for your patient in the treatment of dyslipidemia .
Do not hesitate to contact us at info@mhealthhelptools.es and resolve the doubts about the benefits of Lipidtarget® to make this a purchase satisfactory.
Lipidtarget® is an application for health professionals with responsibility for prescription drugs, which aims to facilitate decision-making on the recommended lipid-lowering therapy in different clinical situations. Lipidtarget® recommendations are aligned with the strategy of "Treat to Target”, which consider Low Density Lipoprotein cholesterol (LDL-C) as the primary goal of treatment, and follows the leading European clinical practice guidelines 1.2, based on scientific evidence available 3. According to the lipid profile given, Lipidtarget® could make recommendations for the control of other objectives as non High Density Lipoprotein cholesterol (non HDL-C) and / or triglicéridos 4. Lipidtarget® makes recommendations but not requirements because they are a direct responsibility of the health professional who will account for this, the characteristics of the drug prescribed (on label) and clinical profile of the patient being treated. In this sense, Lipidtarget® should never replace the clinical judgment of health professionals. The authors of Lipidtarget® are not responsible of inappropriate, irresponsible or fraudulent use of any of the recommendations could give. BIBLIOGRAPHY
Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipideamias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1878. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines in cardiovascular disease prevention in clinical practice (version 2012). The Fith Joint Task Force of The European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in clinical Practice. Eur Heart J doi: 10.1093/eurheartj/ehs092 Mahley RW, Bersot TP. Goodman and Gilman's.The Pharmacological Basis of Therapeutics. New York: McGraw Hill; 2005. p. 933–66 Berglund, L.; Brunzell, J.D.; Goldberg, A.C.; Goldberg, I.J.; Sacks, F.; Murad, M.H.; Stalenhoef, A.F. Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97, 2969–2989.
Recent changes: A quick and easy tool. Developed by healthcare professionals for healthcare professionals .
Save time, in 3 quick steps Lipidtarget® recommends proper treatment to achieve the objectives for your patient in the treatment of dyslipidemia .
Do not hesitate to contact us at info@mhealthhelptools.es and resolve the doubts about the benefits of Lipidtarget® to make this a purchase satisfactory.
Are you the developer of this app? Join us for free to see more information about your app and learn how we can help you promote and earn money with your app.
We don't have enough comments to generate tag clouds.
Please check back later.
Google Play Rankings
This app is not ranked
Permissions
Network communication
Google Play license check
Technologies used by Lipidtarget®
We haven't collected library information for this app yet. You can use the AppBrain Ad Detector app to detect libraries in apps installed on your device.
AppBrain Intelligence premium content
Subscribe now to get full and unlimited access to AppBrain Intelligence.
You'll have access to:
Unlimited pageviews (both app and developer details)
Each subscription will automatically renew 3 days before the expiration date for
the same time period. Subscriptions can be cancelled at any time before the renewal.